Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Articles

Lipid-based formulations offer a means of addressing the physicochemical and biological challenges of poorly soluble APIs.

Developing Lipid-Based Formulations

Vetter chose a winner from four teams that worked for three months to develop ideas for applying digital technology to injectable pharmaceuticals. 

Vetter Awards Winner of Open Innovation Challenge

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

3D printing is being explored as a manufacturing method for on-demand, personalized medicine.

Considering 3D Printing for Solid Dosage Forms

As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.

FDA Expands NDMA Investigation to All ARB Class Drugs

Senomyx uses an approach, known as taste-blocking, to address the challenges of bitter APIs. Kenneth J. Simone, vice-president of Pharmaceutical Business Development, Senomyx, speaks with Pharmaceutical Technology about this technology. 

Taste-Blocking—An Alternative to Tastemasking

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Sharing know-how can help resolve common bio/pharma technical challenges.

Be a Part of the Solution

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Existing software tools cannot take into account the complexity of disease.

Can Artificial Intelligence Take the Next Step for Drug Repositioning?

Marc Brown, PhD, is chief scientific officer and co-founder of MedPharm.

Sarah Pratt is chief operating officer at MedPharm.

Christopher Harrison, is head of Process Development and Manufacture at MedPharm.

Using a QbD approach in the development and formulation of topical products will enable the drug developer to provide a robust control strategy for manufacturing.

QbD Strategies to Secure the Scale-Up of Semi-Solid Topical Formulations

Paul Kippax is product manager at Malvern Instruments.

Jennifer Burt is applications specialist at Malvern Panalytical.

Carolyn O'Grady is UK applications manager at Malvern Panalytical.

This article examines IVBE testing requirements for topical creams and explores some of the analytical techniques necessary. 

Testing Topicals: Analytical Strategies for the In-Vitro Demonstration of Bioequivalence

Jeff Williamson is director of Product Development at Lonza.

API-in-capsule approaches enable pharmaceutical companies to quickly assess new drug candidates with reduced API consumption and to increase speed to clinic.